6/14/2010. GnRH=Gonadotropin-Releasing Hormone.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "6/14/2010. GnRH=Gonadotropin-Releasing Hormone."

Transcription

1 Male Androgen Replacement Mitchell Sorsby, MD June 19, QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression d) nocturia e) fatigue QUESTION # 2 Which of the following is not an adverse effect of T therapy? a) polycythemia b) causes prostate CA c) worsening sleep apnea d) prostatism e) increased PSA level 1

2 QUESTION # 3 Which parameter does not need to be monitored with testosterone therapy? a) Comprehensive metabolic panel b) CBC c) PSA d) Digital prostate exam e) Testosterone level QUESTION # 4 Which of the following are not appropriate forms of Testosterone therapy? a) Oral b) Buccal tablets c) Transdermal patches d) Transdermal gel e) IM injection Primary Hypogonadism Secondary Combination 2

3 Testicular Due Due 6/14/2010 Primary Hypogonadism Testicular failure to produce testosterone Due to Klinefelter syndrome, cryptorchidism, vanishing testis syndrome, bilateral torsion, orchitis, orchiectomy, chemotherapy or toxic damage from radiation, alcohol, or heavy metals Fauci AS, Braunwald E, et al (eds). Harrison's Principles of Internal Medicine. 14th Edition. McGraw-Hill Book Company. New York Secondary Hypogonadism Hypothalamic-pituitary pituitary failure to stimulate testicular testosterone production Due to gonadotropin or GnRH deficiency (idiopathic or Kallman syndrome), pituitary- hypothalamic injury from tumors, trauma, or radiation Hyperprolactinemia GnRH=Gonadotropin-Releasing Hormone. Fauci AS, Braunwald E, et al (eds). Harrison's Principles of Internal Medicine. 14th Edition. McGraw-Hill Book Company. New York Combination Hypogonadism -Hypothalamic and testicular changes associated with: Aging Sickle cell disease Alcoholism Hemochromatosis Chronic illnesses Fauci AS, Braunwald E, et al (eds). Harrison's Principles of Internal Medicine. 14th Edition. McGraw-Hill Book Company. New York

4 Bound Free Unbound Free 6/14/2010 COMBINED DEFECT- DIAGNOSTIC DILEMMA Testosterone LH PRIMARY low high SECONDARY low low-nl COMBINED low low-nl Testosterone in Normal Males 2% free testosterone (unbound) 30% tightly bound to SHBG 2% free testosterone (unbound) and 68% loosely bound to albumin constitute the 70% of bioavailable testosterone SHBG=Sex Hormone-Binding Globulin. 68% loosely bound to albumin 1. AACE Hypogonadism Task Force. Endocri Pract. 2002;8: Winters SJ et al. Clin Chem. 1998;44: Testosterone in Normal Males Total Testosterone Bound testosterone: Albumin/SHBG (98%) 1 Free testosterone (2%) 1 Free Testosterone Unbound testosterone (2%) 1 Bioavailable Testosterone Free and albumin-bound bound testosterone (70%) 2 SHBG=Sex Hormone-Binding Globulin. 1. AACE Hypogonadism Task Force. Endocri Pract. 2002;8: Winters SJ et al. Clin Chem. 1998;44:

5 TESTOSTERONE MEASUREMENTS Total testosterone- accurate methodology but varies with SHBG levels. Bioavailable T- accurate methodology and avoids variations in SHBG binding Free T by equilibrium dialysis- accurate but time consuming and expensive CIRCADIAN RHYTHMICITY OF TESTOSTERONE SECRETION In young men testosterone levels are highest in the early morning and drop significantly in the late afternoon. This rhythmicity is attenuated in older men. Serum levels of testosterone have frequent spikes and nadirs. To diagnose hypogonadism in younger men early morning samples are needed. In older men the time of day of sampling is not important. Measurement of Serum Testosterone Levels Circulation Variation in Serum Testosterone in Normal Males Serum Testosterone (ng/dl) Young (23-28 yrs) Clock Time (hours) Bremner WJ et al. J Clin Endocrinol Metab.1983;56: Old (58-82 yrs)

6 Diagnostic Testosterone Testing Additional Tests: LH To ascertain whether cause is primary or secondary Serum prolactin High prolactin levels may suggest presence of pituitary tumor Tenover JL. Endocrinol Metab Clin North Am. 1998;27: LABORATORY TESTS Total T, LH, Prolactin- morning specimen Total T <200 ng/dl is definitely abnormal- if LH is not elevated obtain MRI of pituitary/hypothalamus Total T ng/dl /dl- check bioavailable T or free T by equilibrium dialysis. MRI if LH is not elevated or prolactin is increased Gonadal Effects of Aging Decline in testosterone production Decreased testosterone levels Increased SHBG levels Decreased free T levels Tenover JL. Endocrinol Metab Clin North Am. 1998;27:

7 DECLINING TESTOSTERONE LEVELS WITH AGING Results from a dual defect in Leydig cell function and the hypothalamic-pituitary pituitary axis. Peripheral- decreased Leydig cell number and response to HCG Central- in older men the LH pulses are diminished. The central defect lies at the level of the hypothalamus as demonstrated by the normal pituitary response to gonadotropin releasing hormone administration. LH and Prolactin are usually normal DECLINING TESTOSTERONE LEVELS WITH AGING Testosterone levels in studies decrease by approximately 1-1.5% 1.5% per year in men over 40 years of age 1. Haren MT et al. Climacteric. 2002;5(1): Harman SM et al. J Clin Endocrinol Metab. 2001;86(2): WHO DO WE SCREEN FOR HYPOGONADISM? 7

8 The ADAM Questionnaire 1. Do you have a decrease in libido (sex drive)? 2. Do you have a lack of energy? 3. Do you have a decrease in strength and/or endurance? 4. Have you lost height? 5. Have you noticed a decreased enjoyment of life? 6. Are you sad and/or grumpy? 7. Are your erections less strong? 8. Have you noticed a recent deterioration in your ability to play sports? 9. Are you falling asleep after dinner? 10. Has there been a recent deterioration in your work performance? (Note: Positive questionnaire result is defined as a yes answer to questions 1 or 7 or any 3 other questions.) Morley JE. J Gend Specif Med. 2001;4(2): PHYSICAL EXAMINATION Decreased muscle mass Decreased body hair Gynecomastia Testicular atrophy TESTOSTERONE REPLACEMENT THERAPY: Risks & Concerns 24 8

9 Increased Increased 6/14/2010 Goals and Benefits of Testosterone Therapy Restore libido and improve erectile function 1-3 Improve lean body mass 2,3 Decrease total body fat 3 Improve bone density 1,2 Improve psychological disposition 1-3 Improve energy level 3 Improve mood/sense of well being 2,3 1. Hypogonadism Task Force. Available at: Accessed on June 22, Tenover JL. Endocrinol Metab Clin North Am. 1998;27: Wang C, Swerdloff RS, Iranmanesh A, et al. JCEM. 2000;85: Concerns of Testosterone Replacement Therapy Polycythemia Increased red blood cell mass Increased hemoglobin and hematocrit Increases in PSA levels possible prostate changes Gynecomastia Sleep apnea PSA=Prostate-Specific Antigen. Morales A et al. J Urol. 2000;163: Concerns of Testosterone Replacement Therapy A PSA increase of 1.5 ng/dl in 2 years,.75 ng/dl/yr for 2 consecutive years or an absolute level >4ng/dl is cause for concern and urologic evaluation 9

10 Infrequent Boost PSA, No Testosterone Supraphysiologic Discomfort 6/14/2010 Concerns of Testosterone Replacement Therapy Prostate Cancer PSA, a marker for prostate cancer, may change with testosterone replacement therapy 1 No evidence that normalization of testosterone with testosterone replacement therapy induces prostate cancer 1 Testosterone replacement therapy is contraindicated in persons with prostate cancer 2 PSA=Prostate-Specific Antigen. 1. Gersten B et al. J Androl. 2002;23(6); Vermeulen A. J Clin Endocrinol Metab. 2001;86(6): Testosterone Therapy Delivery Systems Oral tablets Intramuscular injections Transdermal patch Transdermal gel Applied to upper arms, shoulders, and abdomen Buccal testosterone Testosterone pellets Winters SJ. Arch Fam Med. 1999:8; Testosterone Replacement Therapy: Injectable Advantages Infrequent dosing Boost effect Cost Limitations Supraphysiologic testosterone levels initially Sub-therapeutic levels at end of injection cycle Discomfort of injection Roller-coaster effect Morales A et al. J Urol. 2002;163:

11 High High May C 6/14/2010 Testosterone Replacement Therapy: Transdermal Patches Advantages Noninvasive application Normalization of serum testosterone levels Once-a-day dosing Convenient application sites Limitations rate of dermal reactions discontinuation rate be inconvenient to apply min levels on treatment below baseline trough levels 1 Cost* 1. Steidle C et al. J Clin Endocrinol Metab [In press.]. TESTOSTERONE REPLACEMENT THERAPY- BUCCAL TABLETS Advantages Easy application No skin irritation Limitations Twice daily application Gum irritation Little clinical experience Cost Striant (testosterone buccal system) 11

12 Once-a-day Normalizes Convenient Potential 6/14/2010 Testosterone Replacement Therapy: Transdermal Gels Advantages dosing testosterone levels within 24 hours application sites: shoulders and upper torso Limitations for transfer to partner or child Cost** AndroGel Recommended Application Sites Abdomen Shoulders Upper arms Unimed Pharmaceuticals, Inc. AndroGel (testosterone gel) 1% CIII product information. PATIENT MONITORING Baseline- Breast exam (gynecomastia), DRE, PSA, hematocrit Followup- DRE, PSA, hematocrit at 3,6 and 12 months and annually thereafter. Decrease dosage or discontinue therapy if- Hct >54% Urologic evaluation if- increase in PSA of >1.4 ng/ml between 2 individual measurements or 1.5 ng/ml over 2 years Andropause consensus conference

13 QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression d) nocturia e) fatigue QUESTION # 2 Which of the following is not an adverse effect of T therapy? a) polycythemia b) causes prostate CA c) worsening sleep apnea d) prostatism e) increased PSA level QUESTION # 3 Which parameter does not need to be monitored with testosterone therapy? a) Comprehensive metabolic panel b) CBC c) PSA d) Digital prostate exam e) Testosterone level 13

14 QUESTION # 4 Which of the following are not appropriate forms of Testosterone therapy? a) Oral b) Buccal tablets c) Transdermal patches d) Transdermal gel e) IM injection 14

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008

More information

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical

More information

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,

More information

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely

More information

Recognizing and Managing Testosterone Deficiency

Recognizing and Managing Testosterone Deficiency Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships

More information

ANDROGEN DEFICIENCY Update on Evaluation and Management

ANDROGEN DEFICIENCY Update on Evaluation and Management ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of

More information

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen

More information

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.

More information

Implantable Hormone Pellets

Implantable Hormone Pellets Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Testosterone Injection and Implant

Testosterone Injection and Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone

More information

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees MALE HYPOGONADISM MALE HYPOGONADISM

TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees MALE HYPOGONADISM MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (testosterone deficiency) and in some instances normal

More information

Testosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder

Testosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018

More information

Point-Counterpoint: Late Onset Hypogonadism (LOH)

Point-Counterpoint: Late Onset Hypogonadism (LOH) Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx

More information

TUE Application for Testosterone Physician Worksheet

TUE Application for Testosterone Physician Worksheet TUE Application for Testosterone Physician Worksheet Attention Physicians - USADA will not process Therapeutic Use Exemptions (TUE) for the use of testosterone unless all of the requirements for documentation

More information

in Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University

in Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University Common Endocrine Problems Seen in Primary Care (Part 2) Lecture #34 Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University None Conflict of Interest Topics to be Covered

More information

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation

More information

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of

More information

HORMONE BALANCE QUESTIONNAIRE FOR MEN

HORMONE BALANCE QUESTIONNAIRE FOR MEN HORMONE BALANCE QUESTIONNAIRE FOR MEN Name: Date: Address: City: State: Zip: Home Phone: Cell Phone: Work Phone: Date of Birth: Age: Height: Weight: Primary Care Doctor: Health History Do you have a personal

More information

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine

More information

Laboratory Investigation of Male Gonadal Function. Dr N Oosthuizen Dept of Chemical Pathology UP 2010

Laboratory Investigation of Male Gonadal Function. Dr N Oosthuizen Dept of Chemical Pathology UP 2010 Laboratory Investigation of Male Gonadal Function Dr N Oosthuizen Dept of Chemical Pathology UP 2010 1 Figure 1. Hypothalamic-pituitary pituitary-testicular testicular axis 2 Testosterone (T) measurement

More information

Metastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942

Metastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years

More information

ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM

ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM First published in July 2003 by Andrology Australia 5th Edition, December 2015 Copyright

More information

HIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings

HIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings HIGHLIGHTS From Testosterone Update Disease State Theater Presentations held at the 2008 American Urological Association and Endocrine Society Annual Meetings Jointly sponsored by the Annenberg Center

More information

Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507

Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507 Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.

Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology

More information

Testosterone Therapy in Men An update

Testosterone Therapy in Men An update Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None

More information

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone

More information

ISSN: (print), (electronic)

ISSN: (print), (electronic) http://informahealthcare.com/tam ISSN: 1368-5538 (print), 1473-0790 (electronic) Aging Male, 2014; 17(3): 147 154! 2014 Informa UK Ltd. DOI: 10.3109/13685538.2014.908460 ORIGINAL ARTICLE Performance of

More information

Male Hypogonadism. More than just a low testosterone? KM Pantalone Endocrinology

Male Hypogonadism. More than just a low testosterone? KM Pantalone Endocrinology Male Hypogonadism More than just a low testosterone? KM Pantalone Endocrinology Conflicts of Interest None to declare Case 1 A 54 year old man is referred for evaluation of low testosterone The patient

More information

Reproductive Health and Pituitary Disease

Reproductive Health and Pituitary Disease Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives

More information

Prostate Cancer Case Study 2. Medical Student Case-Based Learning

Prostate Cancer Case Study 2. Medical Student Case-Based Learning Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy

More information

Where are the injections given? They are given in the upper outer hip.

Where are the injections given? They are given in the upper outer hip. 1 How do you diagnose low Testosterone in men? Low Testosterone can be diagnosed if you have 3 or more of the following symptoms: lack of libido fatigue insomnia erectile dysfunction (ED) depression loss

More information

Comparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism

Comparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism Brigham Young University BYU ScholarsArchive All Faculty Publications 2017-01-27 Comparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism Karlen Beth Luthy Brigham Young

More information

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV

More information

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd. 4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant

More information

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D. The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,

More information

Hypogonadism and Testosterone: Who Needs Testosterone Replacement? Objectives. Learning Outcome. At the end of this lecture the learner will:

Hypogonadism and Testosterone: Who Needs Testosterone Replacement? Objectives. Learning Outcome. At the end of this lecture the learner will: Hypogonadism and Testosterone: Who Needs Testosterone Replacement? Mikel Gray, PhD, PNP, FNP, CUNP, CCCN, FAANP, FAAN Professor School of Medicine, Department of Urology School of Nursing, Department of

More information

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two

More information

Labrix Clinical Services, Inc.

Labrix Clinical Services, Inc. Labrix Clinical Services, Inc. Advantages of Labrix Clinical Services, Inc. We Cater to the Healthcare Practitioner Labrix sample collection tubes are small; only 1 ml of saliva is required from the patient.

More information

Fundamentals of Testosterone Production in Men

Fundamentals of Testosterone Production in Men Fundamentals of Testosterone Production in Men Dr. HHJ Leliefeld Bruges, Belgium 25-26 September, 2014 PRISM IV Why should we know? Essential for understanding the ratio of diagnosis and treatment of :

More information

Accession #: Patient: Jane Doe Convert to pdf, Save or PRINT >> ADRENAL CHECK

Accession #: Patient: Jane Doe Convert to pdf, Save or PRINT >> ADRENAL CHECK Page 1 of 5 Patient: Jane Doe Tel: (123) 456-7890 Email: test@test.com Sex: Female Age: 36 yr Date of Birth: 1980-12-12 Height: 5 ft 0 in Weight: 135 lbs Waist size: 30 in 1st day of last menses: Day 07,

More information

MALE INFERTILITY & SEMEN ANALYSIS

MALE INFERTILITY & SEMEN ANALYSIS MALE INFERTILITY & SEMEN ANALYSIS DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and mitigate potential

More information

presents with Ken Sekine, MD

presents with Ken Sekine, MD presents Pioneering Technologies For Pellet Hormone Therapy Lifestyle Based Medicine A Primer for Clinicians with Ken Sekine, MD Dr. Sekine is a board certified OB-GYN who has been in private practice

More information

It s only a few days and we ll be meeting in Atlanta! I look forward to seeing all of you.

It s only a few days and we ll be meeting in Atlanta! I look forward to seeing all of you. THE RECEPTOR Message from the Chair Hubert Vesper, PhD, Centers for Disease Control and Prevention Greetings! The 2015 AACC Annual Meeting begins very soon and I would like to take this time to encourage

More information

Aromatase Inhibitors in Male Infertility:

Aromatase Inhibitors in Male Infertility: Aromatase Inhibitors in Male Infertility: The hype of hypogonadism? BEATRIZ UGALDE, PHARM.D. H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1 03 NOVEMBER 2017 PHARMACOTHERAPY ROUNDS Disclosures No conflicts

More information

X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society

X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society 0021-972X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Pharmacokinetics, Efficacy, and Safety of a Permeation-

More information

Diagnosis, Treatment, and Follow-up of Men with Androgen Deficiency

Diagnosis, Treatment, and Follow-up of Men with Androgen Deficiency Physician Performance Measurement Set Approved May 2012 Endocrine Society 2055 L Street, NW, Suite 600 Washington, DC 20036 (P) 202-971-3636 (F) 202-736-9706 endocrine.org Background These clinical performance

More information

Original Policy Date

Original Policy Date MP 5.01.30 Implantable Hormone Pellets Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy created with literature search/12:2013 Return

More information

HORMONE THERAPY IN AGING MALE ATHLETES

HORMONE THERAPY IN AGING MALE ATHLETES DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the

More information

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY The use of hormone therapy for gender transition/affirmation is based on many years of experience treating trans persons. Research on hormone therapy is

More information

The Sexual Medicine Society of North. Adult-Onset Hypogonadism SPECIAL ARTICLE

The Sexual Medicine Society of North. Adult-Onset Hypogonadism SPECIAL ARTICLE SPECIAL ARTICLE Adult-Onset Hypogonadism Mohit Khera, MD, MBA, MPH; Gregory A. Broderick, MD; Culley C. Carson III, MD; Adrian S. Dobs, MD, MHS; Martha M. Faraday, PhD; Irwin Goldstein, MD; Lawrence S.

More information

John Sutton, DO, FACOI, FACE, CCD. Carson Tahoe Endocrinology Carson City, NV KCOM Class of 1989

John Sutton, DO, FACOI, FACE, CCD. Carson Tahoe Endocrinology Carson City, NV KCOM Class of 1989 John Sutton, DO, FACOI, FACE, CCD Carson Tahoe Endocrinology Carson City, NV KCOM Class of 1989 Gonadal Physiology and Disease 3 No Disclosures Gonadal Axis Hypothalamic-pituitary-gonadal Feedback mechanisms

More information

Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl

Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Sexual Medicine Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Jason M. Scovell, Ranjith Ramasamy, Nathan Wilken, Jason R. Kovac and Larry I. Lipshultz

More information

PITUITARY: JUST THE BASICS PART 2 THE PATIENT

PITUITARY: JUST THE BASICS PART 2 THE PATIENT PITUITARY: JUST THE BASICS PART 2 THE PATIENT DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and

More information

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY 0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7

More information

GONADAL FUNCTION: An Overview

GONADAL FUNCTION: An Overview GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?

More information

Female Sexual Hormones Indications and Therapy

Female Sexual Hormones Indications and Therapy Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses

More information

Keywords: Position statement, expert opinion, hypogonadism, men, testosterone, calculated bioavailable testosterone

Keywords: Position statement, expert opinion, hypogonadism, men, testosterone, calculated bioavailable testosterone The Aging Male, December 2007; 10(4): 211 216 WORKSHOP REPORT Functional testosterone: Biochemical assessment of hypogonadism in men Report from a multidisciplinary workshop hosted by the Ontario Society

More information

HYPOTHALAMO PITUITARY GONADAL AXIS

HYPOTHALAMO PITUITARY GONADAL AXIS HYPOTHALAMO PITUITARY GONADAL AXIS Physiology of the HPG axis Endogenous opioids and the HPG axis (exerciseinduced menstrual disturbances) Effects of the immune system on the HPG axis (cytokines: interleukins

More information

Hormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health

Hormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health Hormone Therapy Overview for the Behavioral Health Provider Julie Thompson, PA Fenway Health Continuing Medical Education Disclosure Program Faculty: Julie Thompson, PA Current Position: Physician s Assistant,

More information

Male hypogonadism & testosterone replacement therapy

Male hypogonadism & testosterone replacement therapy Male hypogonadism & testosterone replacement therapy Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported

More information

EAU Guidelines on Male Hypogonadism

EAU Guidelines on Male Hypogonadism EAU Guidelines on Male Hypogonadism G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab European Association of Urology 2016 TABLE OF CONTENTS PAGE 1. INTRODUCTION 4 1.1 Aim 4

More information

Changes of Some Hormones Levels in Patients With Hepatitis B Virus-Related Chronic Liver Disease

Changes of Some Hormones Levels in Patients With Hepatitis B Virus-Related Chronic Liver Disease Original Article Elmer Press Changes of Some Hormones Levels in Patients With Hepatitis B Virus-Related Chronic Liver Disease Ayfer Serin a, c, Mesut Akarsu b, Hale Akpinar b, Ilkay Simsek b Abstract Background:

More information

Pharmacy Policy. Adult transgender hormonal therapy may be approved when all of the following criteria are met:

Pharmacy Policy. Adult transgender hormonal therapy may be approved when all of the following criteria are met: Pharmacy Policy Class: Transgender Hormonal Treatment for Adults Line of Business: Medi-Cal Effective date: February 15, 2017 Revision date: February 15, 2017 This policy has been developed through review

More information

Andropause state of the art 2015 and review of selected aspects

Andropause state of the art 2015 and review of selected aspects DOI: 10.5114/pm.2015.49998 Prz Menopauzalny 2015; 14(1): 1-6 Featured paper Andropause state of the art 2015 and review of selected aspects Grzegorz Jakiel 1, Marta Makara-Studzińska 2, Michał Ciebiera

More information

Action of reproductive hormones through the life span 9/22/99

Action of reproductive hormones through the life span 9/22/99 Action of reproductive hormones through the life span Do reproductive hormones affect the life span? One hypothesis about the rate of aging asserts that there is selective pressure for either high rate

More information

Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation

Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation Natan Bar-Chama MD Director Male Reproductive Medicine and Surgery The Mount Sinai School of Medicine New York NY American Association

More information

Therapeutic Cohort Results

Therapeutic Cohort Results Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7

More information

Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study

Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.619 Sexual Dysfunction/Male Infertility Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study Sungmin

More information

Advanced Prostate Cancer. November Jose W. Avitia, M.D

Advanced Prostate Cancer. November Jose W. Avitia, M.D Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000

More information

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of

More information

Natesto (testosterone) nasal gel CIII Initial U.S. Approval: 1953

Natesto (testosterone) nasal gel CIII Initial U.S. Approval: 1953 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NATESTO safely and effectively. See full prescribing information for NATESTO. Natesto (testosterone)

More information

Harbor-UCLA Medical Center Division of Endocrinology and Metabolism

Harbor-UCLA Medical Center Division of Endocrinology and Metabolism LABioMed Harbor-UCLA Medical Center Division of Endocrinology and Metabolism Reversible Contraceptive Method for Men Niloufar Ilani, M.D. Endocrine Fellow Introduction Unintended pregnancy remains a major

More information

See accompanying complete Prescribing Information for TESTOPEL.

See accompanying complete Prescribing Information for TESTOPEL. See accompanying complete Prescribing Information for. Testopel Means... No Pain, All Gain Month 1 Month 2 Month 3 Month 4 Months 5 or 6 Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Testosterone

More information

Learning Objectives. The Impact of Testosterone. Diagnosis of Androgen Deficiency and Late Onset Hypogonadism (LOH) Prevalence of Androgen Deficiency

Learning Objectives. The Impact of Testosterone. Diagnosis of Androgen Deficiency and Late Onset Hypogonadism (LOH) Prevalence of Androgen Deficiency 1:45 2:3 pm Tackling Common GU Issues in Men SPEAKER Culley C. Carson, MD, FACS, FRCS (hon) Presenter Disclosure Information The following relationships exist related to this presentation: Culley C. Carson,

More information

One Day Hormone Check

One Day Hormone Check One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND

More information

BPH: a present and future perspective on health impact

BPH: a present and future perspective on health impact BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with

More information

How to Raise Testosterone with Arimidex

How to Raise Testosterone with Arimidex How to Raise Testosterone with Arimidex Awhile back, I discussed how I decided to raise my testosterone level and how I did it. Basically, my doctor prescribed me anastrozole (trade name Arimidex), an

More information

PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS

PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine

More information

Compounding Options for Female and Male Patients

Compounding Options for Female and Male Patients Compounding Options for Female and Male Patients Bruce Biundo, RPh and Andrea Branvold, RPh 2016 Las Vegas Hormone Replacement Therapy Symposium Las Vegas, NV February 11 13, 2016 Men s Health: Treating

More information

Andropause: Current concepts

Andropause: Current concepts Review Article Andropause: Current concepts Parminder Singh Division of Endocrinology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India ABSTRACT Andropause or late-onset hypogonadism is a

More information

Sexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju

Sexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon.  DOI: /kju www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone

More information

Abstract and Introduction. Topical/transdermal Therapies

Abstract and Introduction. Topical/transdermal Therapies www.medscape.com Testosterone Replacement Therapy for Male Hypogonadism: Part III. Pharmacologic and Clinical Profiles, Monitoring, Safety Issues, and Potential Future Agents A Seftel Int J Impot Res.

More information

11: Androgen deficiency and replacement therapy in men

11: Androgen deficiency and replacement therapy in men 11: Androgen deficiency and replacement therapy in men While androgen replacement therapy is essential and effective in overt deficiency, it is no anti-ageing elixir David J Handelsman and Jeffrey D Zajac

More information

Informed Consent Form for Feminizing Medications

Informed Consent Form for Feminizing Medications Student Health Services Oregon State University, 201 Plageman Building, Corvallis, Oregon 97331-8567 Tel 541-737-9355 General Fax 541-737-4530 Medical Fax 541-737-9665 http://studenthealth.oregonstate.edu/

More information

A Clinical Conundrum: The Diagnosis and Treatment of Androgen Deficiency in Older Men

A Clinical Conundrum: The Diagnosis and Treatment of Androgen Deficiency in Older Men IMPROVING PATIENT CARE THROUGH ESOTERIC LABORATORY TESTING SEPTEMBER 2007 A Clinical Conundrum: The Diagnosis and Treatment of Androgen Deficiency in Older Men Testosterone replacement in young men with

More information

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although

More information

Off label therapies for testosterone replacement

Off label therapies for testosterone replacement Review Article Off label therapies for testosterone replacement Lorenzo DiGiorgio 1, Hossein Sadeghi-Nejad 2 1 Division of Urology, Rutgers New Jersey Medical School, Newark, NJ, USA; 2 Hackensack University

More information

We are gong to focus on: Unit 9. Before we begin: Chronic Renal Failure/Uremia ESRD/Dialysis Prostate Cancer Testicular Cancer Renal Cancer

We are gong to focus on: Unit 9. Before we begin: Chronic Renal Failure/Uremia ESRD/Dialysis Prostate Cancer Testicular Cancer Renal Cancer Unit 9 Problems with excretion Before we begin: You are to understand on your own: A & P of Renal System Common terms of renal system How to perform a focused health history How to perform a Physical Exam

More information

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5 Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts

More information

Appendix D Answers to the KAP Survey

Appendix D Answers to the KAP Survey From Trainer s Resource Book to accompany Management of Men s Reproductive Health Problems 2003 EngenderHealth Appendix D Answers to the KAP Survey In the answer key that follows: The answers appear in

More information

Understanding Klinefelter's or XXY Syndrome (KS)

Understanding Klinefelter's or XXY Syndrome (KS) Understanding Klinefelter's or XXY Syndrome (KS) LAWLEY Table of Contents What is Klinefelter's Syndrome (KS)? 1 Recognising KS 1 Babies and Toddlers 2 School-Age Boys 3 Puberty 3 Adult Men 4 KS Facts

More information